source
- Melanoma vaccine shows 42% risk reduction at ESMO 2026, but shares tumble on early data releaseModerna and Merck presented Phase 3 results for their melanoma vaccine intismeran autogene at the European Society for Medical Oncology meeting. The trial reported a 42% reduction in the relative r…
- Corxel to go public via $300 million SPAC merger, advancing GLP-1 pill CX11 and amylin candidateCorxel Pharmaceuticals announced it will become a public company by merging with the SPAC Amanat Acquisition Corp., accompanied by a $300 million private investment. The transaction will fund the…